Karyopharm Therapeutics Inc KPTI.OQ KPTI.O is expected to show a rise in quarterly revenue when it reports results on November 3 for the period ending September 30 2025
The Newton Massachusetts-based company is expected to report a 6.3% increase in revenue to $41.212 million from $38.78 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Karyopharm Therapeutics Inc is for a loss of $3.13 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $13.50, about 55.9% above its last closing price of $5.96
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -4.00 | -4.10 | -4.32 | Missed | -5.4 |
Mar. 31 2025 | -4.21 | -4.18 | -2.77 | Beat | 33.7 |
Dec. 31 2024 | -4.32 | -3.92 | -3.60 | Beat | 8.2 |
Sep. 30 2024 | -3.76 | -3.94 | -3.90 | Beat | 1.1 |
Jun. 30 2024 | -4.31 | -4.48 | 2.25 | Beat | 150.2 |
Mar. 31 2024 | -4.93 | -5.01 | -4.80 | Beat | 4.2 |
Dec. 31 2023 | -4.68 | -4.65 | -5.40 | Missed | -16.2 |
Sep. 30 2023 | -4.26 | -4.20 | -4.50 | Missed | -7.1 |
This summary was machine generated October 31 at 14:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)